Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 7/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.36 |
| ▸ | ITK | Q08881 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.32 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31221963 | 0.85 | SYK (0.44) | RORCSYKEGLN2ITKEGFR | |
| SCHEMBL30954955 | 0.83 | RORC (0.41) | RORCSYKEGLN2ARMAP4K4 | |
| SCHEMBL31221957 | 0.77 | MAPKAPK2 (0.40) | RORCSYKARMAP4K4NAMPT | |
| SCHEMBL30954991 | 0.74 | RORC (0.39) | RORCSYK | |
| SCHEMBL29813612 | 0.72 | SYK (0.45) | RORCSYKEGLN2ARMAP4K4 | |
| SCHEMBL15081332 | 0.72 | SYK (0.45) | RORCSYKEGLN2ARMAP4K4 | |
| SCHEMBL2015768 | 0.71 | SYK (0.44) | RORCSYKEGLN2ARMAP4K4 | |
| SCHEMBL30004261 | 0.71 | SYK (0.44) | RORCSYKEGLN2ARMAP4K4 | |
| SCHEMBL29178680 | 0.71 | SYK (0.44) | RORCSYKEGLN2ARMAP4K4 | |
| SCHEMBL29509761 | 0.71 | SYK (0.44) | RORCSYKEGLN2ARMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626546-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2025-10-08 | — | — | EP | disclosed |
| US-20240217957-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-07-04 | — | — | US | disclosed |
| WO-2024116086-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217957-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, NPY2R | RORC 180/4885SYK 2057/4885EGLN2 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.